Institutional Repository

Physicochemical and nanomedicine applications of phyto-reduced erbium oxide (Er2O3) nanoparticles

Show simple item record

dc.contributor.author Mohamed, Hamza E. A.
dc.contributor.author Khalil, Ali T.
dc.contributor.author Hkiri, Khaoula
dc.contributor.author Ayaz, Muhammad
dc.contributor.author Abbasi, Jamil A.
dc.contributor.author Sadiq, Abdul
dc.contributor.author Ullah, Farhat
dc.contributor.author Nawaz, Asif
dc.contributor.author Ullah, Ikram
dc.contributor.author Maaza, Malik
dc.date.accessioned 2023-03-01T04:47:43Z
dc.date.available 2023-03-01T04:47:43Z
dc.date.issued 2023-02-25
dc.identifier.citation AMB Express. 2023 Feb 25;13(1):24
dc.identifier.uri https://doi.org/10.1186/s13568-023-01527-w
dc.identifier.uri https://hdl.handle.net/10500/29834
dc.description.abstract Abstract Hyphaene thebaica fruits were used for the fabrication of spherical erbium oxide nanoparticles (HT-Er2O3 NPS) using a one-step simple bioreduction process. XRD pattern revealed a highly crystalline and pure phase with crystallite size of ~ 7.5 nm, whereas, the W–H plot revealed crystallite size of 11 nm. FTIR spectra revealed characteristic Er-O atomic vibrations in the fingerprint region. Bandgap was obtained as 5.25 eV using K-M function. The physicochemical and morphological nature was established using Raman spectroscopy, reflectance spectroscopy, SAED and HR-TEM. HT-Er2O3 NPS were further evaluated for antidiabetic potential in mice using in-vivo and in-vitro bioassays. The synthesized HT-Er2O3 NPS were screened for in vitro anti-diabetic potentials against α-glucosidase enzyme and α-amylase enzyme and their antioxidant potential was evaluated using DPPH free radical assay. A dose dependent inhibition was obtained against α-glucosidase (IC50 12 μg/mL) and α-amylase (IC50 78 μg/mL) while good DPPH free radical scavenging potential (IC50 78 μg mL−1) is reported. At 1000 μg/mL, the HT-Er2O3 NPS revealed 90.30% and 92.30% inhibition of α-amylase and α-glucosidase enzymes. HT-Er2O3 NPs treated groups were observed to have better glycemic control in diabetic animals (503.66 ± 5.92*** on day 0 and 185.66 ± 2.60*** on day 21) when compared with positive control glibenclamide treated group. Further, HT-Er2O3 NPS therapy for 21 days caused a considerable effect on serum total lipids, cholesterol, triglycerides, HDL and LDL as compared to untreated diabetic group. In conclusion, our preliminary findings on HT-Er2O3 NPS revealed considerable antidiabetic potential and thus can be an effective candidate for controlling the post-prandial hyperglycemia. However, further studies are encouraged especially taking into consideration the toxicity aspects of the nanomaterial.
dc.title Physicochemical and nanomedicine applications of phyto-reduced erbium oxide (Er2O3) nanoparticles
dc.type Journal Article
dc.date.updated 2023-03-01T04:47:43Z
dc.language.rfc3066 en
dc.rights.holder The Author(s)


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search UnisaIR


Browse

My Account

Statistics